Novo Nordisk (NVO) shares continued to sink deeper into five-year lows on Monday as developments from Eli Lilly (LLY) outshine the Danish GLP-1 maker. On Tuesday, the company announced a multi-month subscription program for Wegovy. Marley Kayden explains why the headline lifted shares and takes a closer look into the company's price action. Tim Biggam offers more technical insight and an example options trade for Novo Nordisk.